IMR Press / FBL / Volume 19 / Issue 1 / DOI: 10.2741/4194

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
EPCs in vascular repair: how can we clear the hurdles between bench and bedside?
Show Less
1 Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
2 Shanghai Gong Li Hospital, Shanghai 200135, China
3 Unite de Recherche INSERM 972, 94807 Villejuif Cedex, France
Academic Editor:Xinyu Wang
Front. Biosci. (Landmark Ed) 2014, 19(1), 34–48;
Published: 1 January 2014

Endothelial progenitor cells (EPCs) play a fundamental role in the maintenance and repair of damaged vascular endothelium, as well as in new blood vessel formation. Based on this function of EPCs, it has been hypothesized that transfusion of these cells could be an approach to treat vascular disease. While this concept has subsequently been proven in animal models clinical trials have not been encouraging. These discrepancies have limited translation of EPCs from bench to bedside. In this review, by analyzing the reported data from the animal models and clinical trials, we describe the main factors limiting the clinical effects of EPCs infusion and the unfavorable in vivo reactions of the receipts. To facilitate future clinical application of EPCs, a series of strategy to overcome the obstacles have been suggested.

Endothelial Progenitor Cells; Vascular Repair; Colony-Forming Unit-Endothelial Cells; Circulating Angiogenic Cells; Endothelial Colony-Forming Cells
Back to top